DC
PHAT icon

Davenport & Co’s Phathom Pharmaceuticals PHAT Stock Holding History

Davenport & Co’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,000
Closed -$181K – 1198
2024
Q3 		$181K Hold
10,000
– – ﹤0.01% 1113
2024
Q2 		$103K Hold
10,000
– – ﹤0.01% 1100
2024
Q1 		$106K Hold
10,000
– – ﹤0.01% 1092
2023
Q4 		$91.3K Buy
+10,000
New +$86.2K ﹤0.01% 1050

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Davenport & Co's PHAT Position: Q4 2024 in Review

Davenport & Co sold out of Phathom Pharmaceuticals (PHAT) in Q4 2024, closing a stake of 10,000 shares — an estimated $181K sold.

Davenport & Co first reported a position in PHAT in Q4 2023 and held it in 4 quarters. The position peaked at $181K in Q3 2024. 144 funds tracked by Wall St. Rank hold PHAT as of Q4 2024.

  • Davenport & Co reported no remaining Phathom Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Davenport & Co sold 10,000 Phathom Pharmaceuticals shares in Q4 2024, an estimated $181K.
  • Davenport & Co first reported a position in Phathom Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Davenport & Co's Phathom Pharmaceuticals position peaked at $181K in Q3 2024.
  • 144 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2024.

Based on Davenport & Co's 13F filing for Q4 2024, filed 24 Jan 2025.